Prophylactic levetiracetam-induced pancytopenia with traumatic extra-dural hematoma: Case report

Bangash, Omar K.; Simonin, Alexandre; Tsimiklis, Chrisovalantis; Ramakonar, Hari; Honeybul, Stephen

doi:10.1016/j.jocn.2020.08.004

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-term anti-seizure drug regimen Bangash et al (2020) [1] 32 y/M Seizure prophylaxis after extradural haematoma evacuation…”

Section: Author(s) (Year)mentioning

confidence: 99%

“…His WBC gradually improved to 1600/ µl on the 17th day of hospitalization, after which he pursued hospice care as his functional status was severely compromised after the cranial surgery. 2) [1][2][3][4][5][6][7][8][9][10][11][12][13] . The phenomenon has been seen in both the adult and paediatric populations [1][2][3][4] .…”

Section: Introductionmentioning

confidence: 99%

“…2) [1][2][3][4][5][6][7][8][9][10][11][12][13] . The phenomenon has been seen in both the adult and paediatric populations [1][2][3][4] . Usually, the fall in blood counts is drastic and a causal temporal relation with the drug is easy to establish [1,2,5,7] .…”

Section: Introductionmentioning

confidence: 99%

“…The phenomenon has been seen in both the adult and paediatric populations [1][2][3][4] . Usually, the fall in blood counts is drastic and a causal temporal relation with the drug is easy to establish [1,2,5,7] . Consequently, the culprit agent is swiftly identified, and the cessation of use leads to a rapid recovery in counts.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Delayed Recognition of Levetiracetam-induced Pancytopenia

Din

Hussain

Bodrog

2021

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Blood dyscrasias associated with levetiracetam use can be difficult to identify, especially when other potential differential diagnoses are concurrently present. Here we present a 57-year-old man with metastatic adenocarcinoma of unknown primary origin on levetiracetam who initially presented with an in-stent thrombosis of the right external iliac vein and then developed worsening thrombocytopenia followed by pancytopenia. Levetiracetam was not identified as the culprit until other causes like platelet consumption, heparin-induced thrombocytopenia, idiopathic immune thrombocytopenic purpura, and bone marrow involvement by metastatic disease were ruled out.

show abstract

“…Long-term anti-seizure drug regimen Bangash et al (2020) [1] 32 y/M Seizure prophylaxis after extradural haematoma evacuation…”

Section: Author(s) (Year)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Delayed Recognition of Levetiracetam-induced Pancytopenia

Din

Hussain

Bodrog

2021

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

show abstract

Levetiracetam

2020

Reactions Weekly

View full text Add to dashboard Cite

Levetiracetam Mechanisms of Action: From Molecules to Systems

et al. 2022

View full text Add to dashboard Cite

Epilepsy is a chronic disease that affects millions of people worldwide. Antiepileptic drugs (AEDs) are used to control seizures. Even though parts of their mechanisms of action are known, there are still components that need to be studied. Therefore, the search for novel drugs, new molecular targets, and a better understanding of the mechanisms of action of existing drugs is still crucial. Levetiracetam (LEV) is an AED that has been shown to be effective in seizure control and is well-tolerable, with a novel mechanism of action through an interaction with the synaptic vesicle protein 2A (SV2A). Moreover, LEV has other molecular targets that involve calcium homeostasis, the GABAergic system, and AMPA receptors among others, that might be integrated into a single mechanism of action that could explain the antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties of LEV. This puts it as a possible multitarget drug with clinical applications other than for epilepsy. According to the above, the objective of this work was to carry out a comprehensive and integrative review of LEV in relation to its clinical uses, structural properties, therapeutical targets, and different molecular, genetic, and systemic action mechanisms in order to consider LEV as a candidate for drug repurposing.

show abstract

Prophylactic levetiracetam-induced pancytopenia with traumatic extra-dural hematoma: Case report

Cited by 4 publications

References 8 publications

Delayed Recognition of Levetiracetam-induced Pancytopenia

Delayed Recognition of Levetiracetam-induced Pancytopenia

Levetiracetam

Levetiracetam Mechanisms of Action: From Molecules to Systems

Contact Info

Product

Resources

About